Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients

Breast Cancer Research and Treatment
Rui ChenShengchun Liu

Abstract

To assess the predictive role of pretreatment ki67 and Ki67 changes in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular subtypes. 1010 BC patients who had undergone anthracycline and taxane-based NAC from January 2012 to July 2017 were retrospectively analyzed. Clinical and pathological parameters of the patients were retrieved and the predictive factors for NAC response were evaluated. 705 patients showed clinical response (cRes), and 131 patients acquired pathologic complete response (pCR). Patients with higher pretreatment Ki67 (≥ 14%), tumor size ≥ 4 cm, and positive clinical nodal had better clinical therapy response, while patients with negative ER and PR, higher pretreatment Ki67 (≥ 14%), and tumor size < 4 cm were more probable to attain pCR. The pretreatment Ki67 could be used as a predictor of NAC only in luminal subtypes, and 25.5% were identified as an ideal cut-off point to differentiate the cRes from non-cRes cases. Although a decrease in Ki67 had been found in almost all molecular subtypes after NAC, no statistically significant differences were found in the decrease of Ki67 were validated between the cRes and non-cRes group in HER2-rich and triple-negative subtypes (P ...Continue Reading

References

Oct 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearUNKNOWN National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Jun 13, 2009·Breast Cancer Research : BCR·Joan S Lewis-Wambi, V Craig Jordan
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ewan K A MillarRobert L Sutherland
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takayuki IwamotoLajos Pusztai
Apr 3, 2012·Breast Cancer Research and Treatment·Elisabetta MunzoneG Viale
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne F Schott, Daniel F Hayes
Aug 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O BrouckaertP Neven
Oct 27, 2012·Science Translational Medicine·Yinyin YuanFlorian Markowetz
Jul 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gunter von MinckwitzCarsten Denkert
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C DenkertG von Minckwitz
Nov 10, 2013·Journal of the National Cancer Institute·Mei-Yin C PolleyUNKNOWN International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group
Apr 20, 2014·Journal of breast cancer·Kwan Il KimHeung Kyu Park
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frederick KlauschenGunter von Minckwitz
Mar 18, 2015·Nature Reviews. Clinical Oncology·Fabrice AndreSuzette Delaloge
Sep 5, 2015·International Journal of Clinical Oncology·Yukie EnomotoYasuo Miyoshi
Feb 6, 2016·Breast Cancer Research and Treatment·Brandon S SheffieldStephen K L Chia
Dec 22, 2016·Cancer Medicine·Li Yan LimMikael Hartman
Jan 31, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansGabriel N Hortobagyi
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi

❮ Previous
Next ❯

Citations

Jan 27, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Panli LiGang Huang
Aug 20, 2019·Breast Cancer Research and Treatment·Giuseppe VialePatrick Maisonneuve

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SPSS

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.